Randomized PRIME (N=151)
DUPIXENT
300 mg Q2W after 600 mg loading dose for 24 weeks (n=75) Matched placebo for 24 weeks (n=76) PRIME2 (N=160)
DUPIXENT
300 mg Q2W after 600 mg loading dose for 24 weeks (n=78) Matched placebo for 24 weeks (n=82) |
||
Study population Adults (>18 years) with:
Over half did not have a history of atopy (defined as having a medical history of AD, allergic rhinitis/rhinoconjunctivitis, asthma, or food allergy). |
||
Primary endpoints1,2 PRIME (N=151)
Week 24
PRIME2 (N=160)
Week 12
|
||
Key secondary endpoints1,2
Week 24
|
||
Among subjects enrolled in the US (n=43), 55% were White, 36% were Black, and 7% were Asian.1 |
AD, atopic dermatitis; IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; TCI, topical calcineurin inhibitors; TCS, topical corticosteroids; WI-NRS, Worst Itch Numeric Rating Scale.